Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 19 |
| Active Pipeline (Recruiting Now) | 5 (4) |
| Completed vs Stopped Early | 10 / 4 (21.1%) |
| Median Closed Actual Enrollment | 69 participants |
| Physical Hospital Site Disclosure | 52.5% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| The Alfred Hospital | Melbourne, Victoria | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | Phase II | RECRUITING |
| NCT05518578 | Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy | Phase II | RECRUITING |
| NCT03597503 | Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Supernus Pharmaceuticals Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.